Inovio Pharmaceuticals (INO) Expected to Announce Earnings on Thursday

Key Points

• Inovio will report Q4 2025 results before the market opens on March 12, 2026, with analysts forecasting a loss of ($0.37) per share and a conference call/webcast at 4:30 PM ET.
• Shares opened at $1.74 (up ~3.6%), trade in a 52-week range of $1.30–$2.98 with a market cap of $116.1M, and the analyst consensus is a Hold with a $6.75 target amid mixed Buy/Hold/Sell ratings.
• Multiple law firms have filed or are soliciting lead plaintiffs in a federal securities class action covering Oct. 10, 2023–Dec. 26, 2025, creating a sustained legal overhang and potential future liability for the company.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) is projected to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Inovio Pharmaceuticals to post earnings of ($0.37) per share for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

Inovio Pharmaceuticals Stock Up 3.6%

INO opened at $1.74 on Friday. Inovio Pharmaceuticals has a 52-week low of $1.30 and a 52-week high of $2.98. The company has a market cap of $116.11 million, a P/E ratio of -0.67 and a beta of 1.70. The firm's 50-day moving average price is $1.65 and its 200-day moving average price is $2.06.

Analysts Set New Price Targets

Several research firms have weighed in on INO. HC Wainwright reissued a "neutral" rating on shares of Inovio Pharmaceuticals in a research report on Tuesday, December 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. UBS Group reiterated an "overweight" rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Finally, Piper Sandler reissued an "overweight" rating and set a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inovio Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $6.75.

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of large investors have recently bought and sold shares of INO. Virtu Financial LLC purchased a new position in Inovio Pharmaceuticals during the 4th quarter worth approximately $77,000. Janus Henderson Group PLC boosted its holdings in shares of Inovio Pharmaceuticals by 1.3% in the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company's stock valued at $5,773,000 after acquiring an additional 42,146 shares during the last quarter. Bridgeway Capital Management LLC purchased a new stake in shares of Inovio Pharmaceuticals in the 4th quarter valued at $301,000. 683 Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the fourth quarter worth $433,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Inovio Pharmaceuticals in the fourth quarter worth $388,000. Hedge funds and other institutional investors own 26.79% of the company's stock.

Inovio Pharmaceuticals News Roundup

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Neutral Sentiment: INOVIO said it will release fourth-quarter and full-year 2025 results after the close on March 12, 2026 and will host a conference call/webcast at 4:30 p.m. ET — this event creates a near-term catalyst for stock movement. INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
• Negative Sentiment: Pomerantz LLP filed a federal class action against Inovio and certain officers alleging violations of the securities laws for the period Oct. 10, 2023–Dec. 26, 2025 — a formal complaint increases legal risk and potential future liability. Pomerantz class action filing
• Negative Sentiment: Multiple plaintiff firms (Schall Law Firm) are soliciting lead-plaintiff candidates in the same securities action, signaling competing claims and sustained media/legal attention through the April 7 lead-plaintiff deadline. Schall Law Firm notice
• Negative Sentiment: Faruqi & Faruqi LLP is investigating claims and reminding investors of the April 7, 2026 lead-plaintiff deadline, adding to the chorus of firms pressing for participation — continued legal notices keep overhang on the shares. Faruqi & Faruqi reminder
• Negative Sentiment: Robbins LLP, Rosen Law Firm, Bronstein Gewirtz & Grossman and others have issued notices urging Inovio investors to contact them about leading or joining the class — multiple firms increase legal publicity and potential litigation costs or settlement pressure. Robbins LLP notice
• Negative Sentiment: Local press coverage and investor alerts (e.g., Bakersfield AP) amplify awareness of the securities-fraud suit, which can deter new buyers until litigation clarity emerges. Bakersfield/AP coverage

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.